Who makes aH5N8c on Day 22?

aH5N8c on Day 22 is developed by Seqirus.

What development phase is aH5N8c on Day 22 in?

aH5N8c on Day 22 is in Phase 2.

Last reviewed 2026-04-19 · How we verify

aH5N8c on Day 22

Seqirus · Phase 2 active Biologic

At a glance

Generic name	aH5N8c on Day 22
Sponsor	Seqirus
Modality	Biologic
Phase	Phase 2

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Study to Evaluate Safety and Immunogenicity of Different Priming and Booster Regimens With Adjuvanted H5N8 and/or H5N6 Influenza Vaccine in Adults (PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

aH5N8c on Day 22 CI brief — competitive landscape report
aH5N8c on Day 22 updates RSS · CI watch RSS
Seqirus portfolio CI